chufangao/CTO huggingface dataset:
Clinical trial NCT03339973: Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD
Official title: A Randomised, Placebo-controlled, Double-blind, Interventional, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-PAOD for the Treatment of Peripheral Arterial Occlusive Disease (PAOD)
Sponsor: RHEACELL GmbH & Co. KG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Very slow recruitment of patients and the current COVID-19 pandemic situation.
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-05
Primary completion date: 2020-05-15
Completion date: 2020-05-15
Plan to share individual participant data: NO
Clinical trial NCT02951429: Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension
Official title: A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic Pulmonary Fibrosis and Intermediate or High Probability of Group 3 Pulmonary Hypertension
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 177.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-31
Primary completion date: 2019-09-26
Completion date: 2020-08-22
Baseline population: ITT Population -
Clinical trial NCT03442985: An Efficacy and Safety Study of Palovarotene for the Treatment of MO
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas
Acronym: MO-Ped
Sponsor: Ipsen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Trial was terminated early to analyze the accumulated data and evaluate the efficacy, safety and future of palovarotene in MO.
Enrollment: 193.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-03-22
Primary completion date: 2020-03-24
Completion date: 2020-10-30
Baseline population: The Safety set included randomized participants who received at least 1 dose of study drug.
Limitations and caveats: The Sponsor terminated the study early due to a partial clinical hold instituted by the Food and Drug Administration. Recruitment was stopped before full enrollment was reached, and study drug administration was discontinued.
Plan to share individual participant data: NO
Clinical trial NCT02446886: Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS
Official title: Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Slow enrollment
Enrollment: 15.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-30
Primary completion date: 2020-03-31
Completion date: 2020-06-30
Plan to share individual participant data: NO
Clinical trial NCT05619536: Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects
Official title: A Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD388 Subcutaneous Administration in Healthy Japanese Subjects
Sponsor: Cidara Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 28.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-10-18
Primary completion date: 2023-07-14
Completion date: 2023-07-14
Baseline population: The Safety Population analyzed consisted of all participants who received any amount of study drug.
Plan to share individual participant data: NO
Clinical trial NCT04158674: Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS
Official title: Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS. Randomized, Controlled, Multicenter, Double-blind, Multicenter Clinical Trial
Acronym: Weanilevo
Sponsor: Centre Hospitalier Universitaire Dijon (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: There was insufficient funding to continue the study in good conditions.
Enrollment: 82.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-24
Primary completion date: 2023-10-11
Completion date: 2023-10-11
Plan to share individual participant data: NO
Clinical trial NCT02101034: PD 0332991 and Cetuximab in Patients With Incurable SCCHN
Official title: Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 96.0 (ACTUAL)
Number of arms: 5.0
Start date: 2014-06-17
Primary completion date: 2020-06-08
Completion date: 2023-11-10
Plan to share individual participant data: NO
Clinical trial NCT03658213: To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.
Official title: An Open Label, Randomised, Parallel Group, Multicentre, Non-inferiority Study to Compare ZOLADEX 10.8 mg With ZOLADEX 3.6 mg in Chinese Pre-menopausal Patients With Estrogen Receptor-Positive and HER2 Negative Early Breast Cancer
Acronym: LARES
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: CTP of LARES has been out of the expire date, we are trying RWS pathway for the indication expend
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-31
Primary completion date: 2021-11-04
Completion date: 2021-11-04
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04612790: A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
Official title: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD)
Acronym: FJORD
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Independent Data Monitoring Committee recommended terminating the study following a pre-planned analysis as the efficacy results did not meet the pre-defined futility guidelines. There were no new safety concerns identified from this analysis.
Enrollment: 67.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-31
Primary completion date: 2023-10-26
Completion date: 2023-10-26
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Clinical trial NCT03331861: Metformin in Heart Failure Without Diabetes
Official title: Metformin in Heart Failure Without Diabetes
Acronym: Met-HeFT
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of funding
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-15
Primary completion date: 2021-08-20
Completion date: 2021-08-20
Limitations and caveats: Study was terminated early, data was unblinded but not analyzed due to low enrollment and lack of statistical power.
Clinical trial NCT02707523: Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children
Official title: Prospective Pilot Clinical Trial of Azithromycin Treatment In RSV-induced Respiratory Failure In Children
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-01-01
Primary completion date: 2019-02-06
Completion date: 2020-06-20
Clinical trial NCT04383938: Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Official title: Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Sponsor: Aprea Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 37.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-06-25
Primary completion date: 2022-04-30
Completion date: 2022-04-30
Clinical trial NCT01258075: Colesevelam for Children With Type 2 Diabetes
Official title: Colesevelam Oral Suspension as Monotherapy or Add-on to Metformin Therapy in Pediatric Subjects With Type 2 Diabetes Mellitus
Acronym: WELKid DM
Sponsor: Daiichi Sankyo (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 236.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-02-24
Primary completion date: 2019-11-01
Completion date: 2020-04-21
Baseline population: Baseline demographic characteristics were assessed in the Randomized Set.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Clinical trial NCT04186299: The Effect of Buccal Infiltration Administration of Clonidine on the Success Rate of Inferior Alveolar Nerve Block
Official title: The Effect of Buccal Infiltration Administration of Clonidine on the Success Rate of Inferior Alveolar Nerve Block on Mandibular Molars With Symptomatic Irreversible Pulpitis: a Randomized Double-blind Clinical Trial
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Study activities never commenced.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-31
Primary completion date: 2022-08-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT05251038: Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Official title: A Phase Ib/II Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of KRAS p. G12C Mutated Advanced Pancreatic Cancer
Sponsor: Hoosier Cancer Research Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Funder Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-09-13
Primary completion date: 2023-01-31
Completion date: 2023-01-31
Plan to share individual participant data: NO
Clinical trial NCT04787250: Bacteriophage Therapy in Patients With Prosthetic Joint Infections
Official title: Randomized Open Label, Parallel Group, Controlled Study to Evaluate the Safety and Surgery Sparing Effect of Phage Therapy With Antibiotics for Patients With Prosthetic Joint Infections Who Are Candidates for Two Stage Exchange Arthroplasty
Sponsor: Adaptive Phage Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Changes to protocol design
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-31
Primary completion date: 2023-05-31
Completion date: 2024-05-31
Plan to share individual participant data: NO
Clinical trial NCT04394650: A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Official title: A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma
Sponsor: Juno Therapeutics, a Subsidiary of Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 78.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-18
Primary completion date: 2024-07-03
Completion date: 2024-07-03
Plan to share individual participant data: YES
IPD sharing description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
IPD time frame: See Plan Description
IPD access criteria: See Plan Description
Clinical trial NCT04826133: Vitamin D and Cocaine Administration
Official title: Testing Restoring Effects of Vitamin D on the Dopamine System: A Human Laboratory Study Among Cocaine Users.
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Could not obtain additional funding to continue the research.
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-27
Primary completion date: 2020-01-17
Completion date: 2020-01-17
Clinical trial NCT01967927: Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy
Official title: Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy
Sponsor: University of Arkansas (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Study has been open for 8 years with no enrollment. Procedures in 2013 protocol are outdated. Cannot make the radiopharmaceutical on campus anymore.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-12-31
Primary completion date: 2021-08-17
Completion date: 2021-08-17
Clinical trial NCT05008835: Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee
Sponsor: ACADIA Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study was terminated for business reasons.
Enrollment: 61.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-07-20
Primary completion date: 2022-08-12
Completion date: 2022-09-08
Plan to share individual participant data: NO
Clinical trial NCT04930042: Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis
Official title: A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Ustekinumab (AVT04) and Stelara® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Sponsor: Alvotech Swiss AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 581.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-03
Primary completion date: 2021-12-28
Completion date: 2022-10-11
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04586335: Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Official title: Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Sponsor: Haihe Biopharma Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 24.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-28
Primary completion date: 2023-02-15
Completion date: 2023-02-15
Plan to share individual participant data: NO
Clinical trial NCT02808143: Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
Official title: A Phase 1 Dose-Escalation Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-10
Primary completion date: 2020-05-15
Completion date: 2022-08-05
Clinical trial NCT03554798: A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine
Official title: A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Novel Oral Polio Type 2 (nOPV2) Vaccine Candidates in Healthy Children Aged 1 to 5 Years and in Healthy Bivalent Oral Polio Vaccine-inactivated Polio Vaccine (bOPV-IPV) Vaccinated Infants
Sponsor: Fidec Corporation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 1025.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-04
Primary completion date: 2020-02-19
Completion date: 2020-02-19
Plan to share individual participant data: NO
Clinical trial NCT02508324: IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Official title: Parallel Phase II Trial of IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual and change in direction of cord blood program
Enrollment: 43.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-09-10
Primary completion date: 2022-06-24
Completion date: 2022-06-24
Baseline population: No subjects were enrolled onto the Haploidentical arm due to graft selection criteria and suitable cord blood units being identified for subjects.
Clinical trial NCT02936037: Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Official title: Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Acronym: SPI2
Sponsor: MedDay Pharmaceuticals SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision for business purposes
Enrollment: 642.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-31
Primary completion date: 2019-11-15
Completion date: 2020-04-23
Plan to share individual participant data: NO
Clinical trial NCT04211415: Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis
Official title: DS-2741a Phase I Study- A Three-part First-in-human Study: Single Ascending Dose and Multiple Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-2741a After Subcutaneous Injection in Healthy Japanese Male Subjects, and Single Dose Study to Assess the Pharmacokinetics, Safety, Pharmacodynamics and Efficacy of DS-2741a After Subcutaneous Injection in Japanese Subjects With Moderate to Severe Atopic Dermatitis.
Sponsor: Daiichi Sankyo (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Company decision of termination of the clinical program.
Enrollment: 8.0 (ACTUAL)
Number of arms: 11.0
Start date: 2020-01-13
Primary completion date: 2020-03-14
Completion date: 2020-12-18
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Clinical trial NCT02794168: Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury
Official title: Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury - (NOSTRA Phase III Trial): A Confirmatory, Placebo-controlled, Randomised, Double Blind, Multi-centre Study
Acronym: NOSTRA-III
Sponsor: veriNOS operations GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 224.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-30
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02705339: Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)
Official title: Genomic Landscape of EGFR Mutant NSCLC Prior to Rociletinib and at the Time of Disease Progression Following Rociletinib
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Clovis Oncology discontinued rociletinib.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-05-31
Primary completion date: 2019-11-30
Completion date: 2020-04-30
Plan to share individual participant data: NO
Clinical trial NCT03740724: A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
Official title: A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
Sponsor: Castle Creek Biosciences, LLC. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-18
Primary completion date: 2020-09-23
Completion date: 2022-04-21
Plan to share individual participant data: NO